Cargando…

Janus Kinase V617F Mutation Detection in Patients with Myelofibrosis

Myelofibrosis (MF) is characterized by a presence of an extra fibrous tissue in the bone marrow and additional hematopoiesis. The somatic mutation in the Janus kinase 2 (JAK2) gene (V617F) occurs gradually and is detected in about 50.0% of myelofibrosis or essential thrombo-cytopenia (ET) patients....

Descripción completa

Detalles Bibliográficos
Autores principales:	Nikolova, D, Yordanov, A, Damyanova, V, Radinov, A, Toncheva, D
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Sciendo 2019
Materias:	Original Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6714340/ https://www.ncbi.nlm.nih.gov/pubmed/31523621 http://dx.doi.org/10.2478/bjmg-2019-0007

Ejemplares similares

PB2040: INTERRELATION BETWEEN JAK2 V617F MUTATION AND THE INCIDENCE OF THROMBOTIC EVENTS IN PATIENTS WITH MYELOPROLIFERATIVE NEOPLASMS
por: Nikolova, D., et al.
Publicado: (2022)

Janus kinase 2 V617F mutation in an unrelated peripheral blood stem cell donor
por: Yang, Shang-Hsien, et al.
Publicado: (2019)

Molecular analysis of V617F mutation in Janus kinase 2 gene of breast cancer patients
por: Karim, Sajjad, et al.
Publicado: (2019)

Megakaryocytic morphology in Janus kinase 2 V617F positive myeloproliferative neoplasm
por: Ghai, Shuchi, et al.
Publicado: (2017)

Adrenal incidentaloma and the Janus Kinase 2 V617F mutation: A case-based review of the literature
por: Unubol, Mustafa, et al.
Publicado: (2013)

Vitamin D Deficiency and Janus kinase 2 V617F Mutation Status in Essential Thrombocythemia and Polycythemia Vera
por: Yikilmaz, Aysun Şentürk, et al.
Publicado: (2020)

Managing Patients With Myelofibrosis in the Era of Janus Kinase Inhibitors
por: Knight, Emily A., et al.
Publicado: (2015)

Detection of the Janus kinase 2 V617F mutation using a locked nucleic-acid, real-time polymerase chain reaction assay
por: Senamela, Tshiphiri, et al.
Publicado: (2018)

Correlations between Janus Kinase 2 V617F Allele Burdens and Clinicohematologic Parameters in Myeloproliferative Neoplasms
por: Ha, Jung-Sook, et al.
Publicado: (2012)

JAK2 V617F, MPL, and CALR Mutations in Korean Patients with Essential Thrombocythemia and Primary Myelofibrosis
por: Kim, Bo Hyun, et al.
Publicado: (2015)

Impact of JAK2V617F Mutational Status on Phenotypic Features in Essential Thrombocythemia and Primary Myelofibrosis
por: Yönal, İpek, et al.
Publicado: (2016)

Janus Kinase-2 V617F Mutation and Antiphospholipid Syndrome in Cerebral Sinus Venous Thrombosis: Natural History and Retrospective Bicenter Analysis
por: Orion, David, et al.
Publicado: (2022)

Cooperative effects of Janus and Aurora kinase inhibition by CEP701 in cells expressing Jak2V617F
por: Gäbler, Karoline, et al.
Publicado: (2013)

Quantitative assay for the detection of the V617F variant in the Janus kinase 2 (JAK2) gene using the Luminex xMAP technology
por: Paradis, François W, et al.
Publicado: (2010)

Immunoproteasome Genes Are Modulated in CD34(+) JAK2(V617F) Mutated Cells from Primary Myelofibrosis Patients
por: Di Rosa, Michelino, et al.
Publicado: (2020)

Detection of Exon 12 and 14 Mutations in Janus Kinase 2 Gene Including a Novel Mutant in V617F Negative Polycythemia Vera Patients from Pakistan
por: Akram, Afia Muhammad, et al.
Publicado: (2018)

Increased risk of thrombosis in JAK2 V617F-positive patients with primary myelofibrosis and interaction of the mutation with the IPSS score
por: Barbui, Tiziano, et al.
Publicado: (2022)

Coexistence of breakpoint cluster region-Abelson1 rearrangement and Janus kinase 2 V617F mutation in chronic myeloid leukemia: A case report
por: Shi, Xue-Bing, et al.
Publicado: (2019)

JAK2 V617F Genotype Is a Strong Determinant of Blast Transformation in Primary Myelofibrosis
por: Barosi, Giovanni, et al.
Publicado: (2013)

Loss of Ezh2 synergizes with JAK2-V617F in initiating myeloproliferative neoplasms and promoting myelofibrosis
por: Shimizu, Takafumi, et al.
Publicado: (2016)

IDH mutations in primary myelofibrosis predict leukemic transformation and shortened survival: clinical evidence for leukemogenic collaboration with JAK2V617F
por: Tefferi, A, et al.
Publicado: (2012)

JAK2 V617F mutation in plasma cell-free DNA preceding clinically overt myelofibrosis: Implications for early diagnosis
por: Choi, Michael Y., et al.
Publicado: (2018)

Primary Myelofibrosis-Related Renal Disorders Treated with a Janus Kinase Inhibitor
por: Asou, Mea, et al.
Publicado: (2021)

MANIFEST: Pelabresib in Combination With Ruxolitinib for Janus Kinase Inhibitor Treatment-Naïve Myelofibrosis
por: Mascarenhas, John, et al.
Publicado: (2023)

Characterization of Glycoproteoforms of Integrins α2 and β1 in Megakaryocytes in the Occurrence of JAK2V617F Mutation-Induced Primary Myelofibrosis
por: Gaye, Maissa M., et al.
Publicado: (2022)

Splenomegaly in myelofibrosis—new options for therapy and the therapeutic potential of Janus kinase 2 inhibitors
por: Randhawa, Jasleen, et al.
Publicado: (2012)

Effect of NS-018, a selective JAK2V617F inhibitor, in a murine model of myelofibrosis
por: Nakaya, Y, et al.
Publicado: (2014)

Inhibition of Osteoblast Differentiation by JAK2(V617F) Megakaryocytes Derived From Male Mice With Primary Myelofibrosis
por: Karagianni, Aikaterini, et al.
Publicado: (2022)

Coexistence of BCR/ABL1-positive chronic myeloid leukemia and JAK2 V617F-mutated myelofibrosis successfully treated with dasatinib and ruxolitinib
por: Yi, Jun Ho, et al.
Publicado: (2019)

Efficacy and tolerability of Janus kinase inhibitors in myelofibrosis: a systematic review and network meta-analysis
por: Sureau, Léa, et al.
Publicado: (2021)

Inhibition of interleukin-1β reduces myelofibrosis and osteosclerosis in mice with JAK2-V617F driven myeloproliferative neoplasm
por: Rai, Shivam, et al.
Publicado: (2022)

Elevated plasma EDA fibronectin in primary myelofibrosis is determined by high allele burden of JAK2V617F mutation and strongly predicts splenomegaly progression
por: Malara, Alessandro, et al.
Publicado: (2022)

Detection of JAK2 V617F mutation increases the diagnosis of myeloproliferative neoplasms
por: ZHANG, SHU-PENG, et al.
Publicado: (2015)

P1005: EFFECT OF TL-895, A NOVEL BRUTON’S TYROSINE KINASE INHIBITOR (BTKI), ON ONCOGENIC JANUS KINASE 2-V617F (JAK2VF) SIGNALING
por: Chary Nimmagadda, Subbaiah, et al.
Publicado: (2023)

The JAK2 V617F mutation in isolated neutropenia
por: Langabeer, Stephen E.
Publicado: (2018)

Translocation t(3;12)(q26;q21) in JAK2(V617F) Point Mutation Negative Chronic Idiopathic Myelofibrosis: A Case Report
por: Mešanović, S., et al.
Publicado: (2014)

ASXL1 mutation confers poor prognosis in primary myelofibrosis patients with low JAK2V617F allele burden but not in those with high allele burden
por: Wang, Yu-Hung, et al.
Publicado: (2020)

Neoplastic fibrocytes play an essential role in bone marrow fibrosis in Jak2V617F-induced primary myelofibrosis mice
por: Ozono, Yoshinori, et al.
Publicado: (2020)

Kinase domain mutations confer resistance to novel inhibitors targeting JAK2V617F in myeloproliferative neoplasms
por: Deshpande, Anagha, et al.
Publicado: (2011)

Paroxysmal nocturnal hemoglobinuria and concurrent JAK2(V617F) mutation
por: Sugimori, C, et al.
Publicado: (2012)

Cannot write session to /tmp/vufind_sessions/sess_r2fpkorac2qnsc1osb7q6cjklv